Cardiac remodeling is pivotal to the progression of heart failure with reduced ejection
fraction (HFrEF; left ventricular [LV] ejection fraction≤ 40%). 1 Therapies that improve …

Background: Angiotensin-converting enzyme inhibitors (ACEI) reduce the mortality in the
chronic phase of myocardial infarction (MI), and similar effects of angiotensin receptor …

Converting Enzyme [ACE] Inhibitors to Determine Impact on Global Mortality and Morbidity
in Heart Failure) subanalysis reporting that therapy with sacubitril/valsartan is associated …

Background The angiotensin‐receptor neprilysin inhibitor (ARNI) sacubitril/valsartan was
shown to be superior to the angiotensin‐converting enzyme inhibitor enalapril in terms of …

Background In real-world clinical practice, the initiation and up-titration of sacubitril/valsartan
remain challenging due to symptomatic hypotension in patients with acute myocardial …

Introduction In 2014, the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to
Determine Impact on Global Mortality and Morbidity in Heart Failure) has shown that …

Background Major classes of medical therapy for heart failure with reduced ejection fraction
(HFrEF) induce reverse remodeling. The revere remodeling response to sacubitril/valsartan …

BACKGROUND: The VALIANT trial compared the efficacy and safety of captopril, valsartan,
and their combination in patients with left ventricular systolic dysfunction, heart failure, or …

Background Left ventricular (LV) remodelling is a major mechanism underlying disease
progression in patients with heart failure (HF) with reduced ejection fraction (EF). Previous …